MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00174369. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with non-small cell lung cancer. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies of a tumor and a blood sample will be taken before treatment to examine the how genes affect tumor response to the study medication. Blood samples will be taken to measure the amount of drug in the blood.
Study identification
- NCT ID
- NCT00174369
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- May 31, 2007
- Completion
- May 31, 2007
- Last update posted
- Mar 16, 2009
2005 – 2007
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Greenbrae | California | 94904 | — |
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | La Jolla | California | 92093 | — |
| Pfizer Investigational Site | San Diego | California | 92103 | — |
| Pfizer Investigational Site | San Mateo | California | 94402 | — |
| Pfizer Investigational Site | Tampa | Florida | 33612 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48106-0995 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Farmington Hills | Michigan | 48334 | — |
| Pfizer Investigational Site | Coon Rapids | Minnesota | 55433 | — |
| Pfizer Investigational Site | Fridley | Minnesota | 55432 | — |
| Pfizer Investigational Site | Robbinsdale | Minnesota | 55422 | — |
| Pfizer Investigational Site | New York | New York | 11725 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00174369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2009 · Synced Sep 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00174369 live on ClinicalTrials.gov.